Abstract
Oral bisphosphonates have proven to be an effective strategy for the prevention and treatment of glucocorticoid-induced osteoporosis; however, information on the efficacy of these agents in patients receiving high-dose glucocorticoid therapy is scarce. In this Practice Point commentary, we discuss the 6-month, randomized, placebo-controlled study of Mok et al., which evaluated the efficacy of 5 mg oral risedronate daily for the prevention of bone loss at the spine and hip in patients receiving high-dose prednisolone therapy (>0.5 mg/kg/day). Risedronate prevented bone loss at the spine and attenuated, but did not prevent, bone loss at the hip. We compare and contrast the findings of Mok et al. with previously published studies of bisphosphonate therapy in glucocorticoid-induced osteoporosis, taking into account the pathophysiology of this condition, and highlight gaps in our knowledge and in current patient care.
References
McDonough AK et al. (2008) The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20: 131–137
Canalis E et al. (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18: 1319–1328
Mok CC et al. (2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 19: 357–364
Sambrook PN et al. (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18: 919–924
Saag KG et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028–2039
Reid DM et al. (2008) A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedonate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck, and trochanter in patients with glucocorticoid-induced osteoporosis. Osteoporos Int 19 (Suppl 1): s23
Marx RE et al. (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65: 2397–2410
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Asma Arabi has received grant/research support from Sanofi-Aventis. Ghada El-Hajj Fuleihan has declared associations with the following companies: Eli Lilly (speakers bureau, grant/research support); Merck Sharp & Dohme (speakers bureau, grant/research support); Novartis (consultant, speakers bureau, grant/research support); and Sanofi-Aventis (grant/research support).
Rights and permissions
About this article
Cite this article
Arabi, A., Fuleihan, GH. How effective is risedronate in preventing bone loss in patients on high-dose steroids?. Nat Rev Endocrinol 4, 540–541 (2008). https://doi.org/10.1038/ncpendmet0923
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0923
- Springer Nature Limited